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Abstract 
Objective: 
To systematically review the impact of depression on subsequent smoking cessation 
in prospective studies of chronic respiratory patients.   
Method: 
A systematic search of electronic databases (MEDLINE, Psychinfo, CINAHL) was 
conducted to identify prospective studies of chronic respiratory patients which 
measured depression at baseline and smoking status at follow-up, dating from 1
st
 
January 1990 to 21
st
 February 2014. The standardised mean difference (SMD) and 95% 
confidence interval for the association between baseline depressive symptoms and 
subsequent smoking cessation was estimated from available data using random effects 
meta-analysis. 
Results: 
A total of 1314 citations were retrieved and 197 articles were further evaluated by two 
reviewers. Seven articles provided sufficient data to estimate the association between 
depressive symptoms and subsequent smoking cessation. Those with elevated 
depressive symptoms were significantly less likely to quit smoking at follow-up than 
those not reporting elevated depressive symptoms (SMD=-.31, 95%CI -.43 to -.19; 
I
2
=0%, p=.506).  
Conclusions: 
The association between depression and subsequent smoking was poorly reported or 
omitted in most studies. However, the available evidence suggests depression 
decreases the likelihood that patients with chronic respiratory conditions will quit 
smoking. Future research is needed to determine how best to manage depression and 
smoking cessation in this population. 
Keywords 
Systematic review; meta-analysis; depression; smoking cessation; chronic respiratory 
disease 
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1. Introduction  
Smoking is a leading cause of preventable death worldwide and accounts for 6 million 
deaths annually [1] and [2]. According to the Centres for Disease Control and 
Prevention, smoking causes 90% of lung cancer deaths and 80% of deaths from 
chronic obstructive pulmonary disease (COPD). To combat this problem, respiratory 
patients are encouraged to quit smoking [1]. According to guidelines, respiratory 
patients have greater urgency to quit smoking and smoking cessation should be 
integrated into the management of respiratory conditions such as COPD [5], [6]. 
Smoking cessation is highly cost-effective and the single most important intervention 
for reducing the risk of respiratory diseases such as COPD, lung cancers [7] and [8], 
and improving respiratory symptoms [7].  However, up to 15-43% of respiratory 
patients continue to smoke post-diagnosis, while approximately 20% do not attempt 
to quit [9]. Therefore, identification of factors that predict smoking continuation and 
relapse is crucial. 
Depression may negatively impact on smoking cessation [1], [10], [13, [14], [15] and 
[16]. Depression is common among patients with chronic respiratory disease [11], 
with up to 40% of patients reporting elevated depressive symptoms [12], [17], [18] 
and [19]. In a recent systematic review, Atlantis et al. [12] described that depression 
was associated with increased risk of mortality in COPD patients, and it is possible 
that smoking continuation partially mediates this association. However, no systematic 
review of the effect of depression on subsequent smoking status has been conducted 
in chronic respiratory patients, and as such it is unclear whether depression truly 
impacts on smoking in this population. Such a study may have important implications 
for the management of such patients. We aimed to fill this gap in the literature.  
 
2. Methods 
As this is a systematic review IRB approval was not required.  
2.1 Search Strategy  
A systematic literature search, following recommended principles [20], of MEDLINE, 
Web of Science, Psychinfo, and CINAHL was performed on 21
st
 January 2014. 
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Searches involved subject headings and keywords (see Appendix A for example). We 
included studies dating from 1
st
 January 1990 to 21
st
 February 2014 in the analysis. 
Additional articles were identified from reference lists of the included articles and we 
also checked citing articles.  
 
2.2 Study Selection and Data Extraction 
We included studies that met the following inclusion criteria: chronic respiratory 
patients (i.e. chronic obstructive pulmonary disease, asthma, lung cancer, chronic 
bronchitis and interstitial lung disease), published in peer-reviewed journals in 1990 
or later, English language, prospective design (observational or randomized trials 
[control groups or full data if controls only data was unavailable]), depression 
measured at baseline (i.e. diagnostic interview, questionnaire, antidepressant 
prescription, single-item questions), and measure of smoking (self-report or objective, 
validated or unvalidated) at follow-up.  
Potentially relevant studies relating to depression and smoking cessation in chronic 
respiratory patients were yielded from multiple electronic databases. Two reviewers 
completed the first screening of abstracts/titles independently (SY.H., N.A.). Articles 
were then excluded because their titles and abstracts revealed that they were not 
relevant or did not fit the eligibility criteria. Studies that were considered eligible for 
inclusion were retrieved and evaluated in full, and suitability for inclusion was 
independently determined by SY. H. and N.A. Disagreements and queries were 
managed by consensus or discussions with a third reviewer (F.D.). Extraction of data 
for each study was based on setting of the study, sample type (i.e. chronic respiratory 
patients), follow-up duration, depression measures and smoking status. Authors were 
contacted to provide further information when there were insufficient data (i.e. 
association between depression and smoking cessation not reported) provided in the 
published paper. 
2.3 Quality Assessment 
The Crowe Critical Appraisal Tool (CCAT) [21], [22] and [23] was used to appraise 
study quality (D.R.), as per a similar review [16]. CCAT scores have exhibited 
adequate reliability and construct validity, and are provided after an objective and 
subjective appraisal of eight categories of study quality with a range of 0-5 each. The 
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total is then expressed as a percentage. As per a previous review, we considered 
higher quality studies to have scores ≥60% [16].  
2.4 Statistical analysis 
The primary outcome was smoking status at follow-up. A priori, we used a 
hierarchical system to establish better depression measures: diagnostic interview, 
validated scale, current prescription of antidepressants, and single-item (unvalidated) 
measure [16]. We also used the standardised mean difference (SMD) as the primary 
outcome measure for two main reasons: the expected differential measurement of 
depression at baseline (e.g. dichotomous or continuous) and smoking status at 
outcome (7-day point prevalence, smoke 20 in last year, etc), and it allowed direct 
comparison to a similar review in patient with coronary heart disease [16].
 
Adjusted 
estimates were used where reported. The metaeff command in Stata 13.1 was used to 
estimate the SMD, and a random effects model was used to conduct the overall 
analysis [24], [25] and [26]. The I
2
 test and Cochran’s Q assessed heterogeneity. Pre-
planned sensitivity analysis included examining the impact of differential depression 
assessment, different durations of follow-up (categorised as <1 year versus ≥1 year), 
higher quality studies (≥60%), adjusted or unadjusted results, objective or self-report 
cessation [16]. 
 
3. Results 
A total of 1314 articles were found (Figure 1). There were 815 articles left after 
removal of duplicates. Upon screening of titles and abstracts, 179 articles were 
selected for evaluation. A further 17 articles were added after searching citations and 
bibliography of the 179 articles resulting in a total of 196 articles for further 
evaluation. Among the 196 articles, 182 papers that did not fit the inclusion criteria 
were excluded, 4 papers were excluded for having too few smokers/quitters (n<5), 3 
papers were repeat publications. Thus, four papers reported the relevant association 
and three provided data on email, leaving seven studies to be included in the meta-
analysis (Table 1) [32], [33], [34], [35], [36], [37] and [38]. An overview of the 
omitted studies is available in Appendix B.  
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Fig 1 about here 
Table 1 about here 
 
3.1 Study characteristics 
The included studies took place across four countries, and the majority concerned 
patients with COPD. Sample sizes ranged from 89-372, with follow-up ranging from 
6-24 months. All studies used a validated depression scale, and three had objective 
measures of cessation at follow-up. Study quality appraisals are available in Appendix 
C.   
3.2 Meta-analysis 
The forest plot is displayed in Fig 2.  
Fig 2 about here 
 
There is a small association between depression and subsequent smoking (SMD=-.31, 
95%CI -.43 to -.19), with no heterogeneity evident (I
2
=3.1%, 95% CI 0.0 to 71.7%, 
p=.402). The Cochran Q statistic was 6.19 (degrees of freedom = 6, p=.402). Egger’s 
test did not reveal any bias (p=0.923; see Appendix for funnel plot).   
3.3 Sensitivity analyses 
Summary estimates for each sensitivity analysis are displayed in Table 2. As all 
studies used questionnaires, no sensitivity analyses could be conducted as per 
depression measurement. The SMD was unchanged for each sensitivity analysis.   
 
Table 2 about here 
 
4. Discussion  
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There are perhaps two main conclusions from this systematic review. Firstly, despite 
the fact that many studies were found that measured depression at baseline and 
smoking status at follow-up, few reported the association between depression and 
subsequent smoking status. The second is that, from the limited estimates we can 
extract from the literature, depressive symptoms are consistently associated with 
reduced probability of quitting smoking in those with chronic respiratory conditions. 
 
  
That the depression-smoking association is largely neglected is worrying, but 
probably unsurprising. For example, a recent review of depression and anxiety in 
COPD demonstrated that these conditions are undetected and undertreated [18]. 
Furthermore, contrary to popular belief, cessation is associated with improved mental 
health [27]. Given the high prevalence of depression in respiratory patients, and the 
impact of depression on outcomes such as health status, health behaviours and 
mortality [1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], 
[17], [18] and [19], this underscores the need for clinicians to address the barriers to 
better management of depressive symptoms in such patients.  
Despite the fact that we could only provide estimates from seven studies, the results 
showed that depressive symptoms had a negative association with smoking cessation. 
The effect size was small, but consistent in various sensitivity analyses. Therefore, not 
only are depressive symptoms likely to impact on the quality of life of those with 
respiratory conditions, they are also stopping them achieving optimal health benefits 
of cessation. It is therefore possible that continued smoking is one of the mediating 
mechanisms behind the increased mortality rate seen in those with depressive 
symptoms in COPD [12] and [18], for example. The fact that depressive symptoms 
negatively impact on smoking cessation has also recently been demonstrated in 
patients with coronary heart disease, with similar effect size estimates [16]. 
While the effect estimates would be considered ‘small’ according to recommended 
guidelines [26], these are clinically significant effects, akin to the effects of anti-
depressants on depressive symptoms [28] and [29]. Also, for an addictive behaviour 
such as smoking, it is likely that even small effects could easily persuade patients to 
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re-commence smoking once they are trying to stop, or stop them from quitting in the 
first instance. Furthermore, even though effect estimates were similar in adjusted and 
unadjusted analyses, the variables accounted for were variable across studies. Hence, 
it is uncertain whether adjustment for other demographic factors (i.e. socioeconomic 
status, age, household smoking etc.), or indeed other variables which predict smoking 
cessation such as higher nicotine dependence, intention to quit or self-efficacy [30] 
would attenuate this association.  
The recommended treatments for smoking cessation in respiratory conditions have 
recently been summarised [1] and [31]. While behavioural support is an effective 
treatment, and patients with depressive symptoms are likely to have less success at 
quitting. However, of particular relevance here is that two antidepressant therapies 
may be important for the depression-smoking link. Nortryptyline has only 
demonstrated non-significant abstinence increases in two randomized trials, and does 
not have FDA approval for cessation treatment. Bupropion demonstrated a significant 
effect on prolonged abstinence rates in COPD smokers [38] and is an approved 
cessation treatment, although adherence appeared to be an issue in that trial.  Further 
research is needed for efficacious interventions in smokers with co-morbid respiratory 
and depressive conditions, and combination therapies have recently been advocated 
[1]. 
There were several limitations to this review. The literature in this area seems to be at 
an early developmental stage, and this warrants more sophisticated future research. 
Due to the limited literature here, the present meta-analysis will require updating once 
futher research is conducted in this area.Secondly, we were only able to include a 
minority of studies in the final meta-analysis. It is unclear if the estimates from other 
research would match those found here. Unfortunately, having so few studies to meta-
analyse increases the likelihood of an error in the mean effect estimate. Thirdly, 
depression in all 7 studies included in this review was measured using questionnaires 
instead of diagnostic interviews, and this could have led to misclassification bias. 
Thirdly, the follow-up duration period for the majority of the studies included ranged 
only from 6-24 months. Even though study duration did not seem to affect the 
estimates, as depression is a chronic illness with phases of relapse, studies with 
repeated measures and longer follow-up duration will be better able to truly measure 
the effect of depression on smoking cessation. It is possible that other confounders 
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may explain the depression-smoking link, as adjustment for confounders was 
heterogeneous in the current findings. However, no real differences were seen 
between overall adjusted and unadjusted estimates. Fourthly, as the depression 
measures used in this literature may not always be able to discriminate depression 
from anxiety or other related negative affect states [40],[41],[42] it is unclear whether 
the results may also be relevant to, or indeed be confounded by, other negative affect 
states such as anxiety. Future research using diagnostic measures should investigate 
this. It must also be noted that the inclusion and exclusion criteria for the studies 
contained within the meta-analysis could differ significantly, thereby limiting 
comparability. Such a limitation is typical of meta-analysis of observational studies 
such as this one [26].  Future research is needed to address these limitations, including 
repeated measures studies with adjustment for multiple confounders, and intervention 
studies to determine the best management methods for both depression and smoking 
cessation. 
 
5. Conclusion 
The association between depression and subsequent smoking was poorly reported or 
omitted in most studies. However, the available evidence suggests that depression 
decreases the likelihood that patients with chronic respiratory conditions will quit 
smoking. Therefore, the present paper should provide impetus for a renewed focus on 
the effects of depression on smoking. Future research is needed to determine how best 
to manage depression and smoking cessation in this population. 
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Figure 1: Flow diagram of selected articles in systematic review  
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Figure 2: Forest plot of the impact of baseline depression on subsequent smoking 
cessation 
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Table 1: Included prospective studies reporting an association between baseline depression and subsequent smoking cessation 
 
Author (Country) Sample 
Description 
Sample 
Size: 
Baseline, 
Follow-Up 
Longest(Mean
/Median) 
Follow-Up 
Duration 
Depression 
Measure 
Smoking 
Outcome Measure 
(Continuation / 
Cessation) 
Results CCAT 
Quality 
score 
Comments 
         
Christenhusz et al.
32 
(The Netherlands) 
Chronic 
obstructive 
pulmonary 
disease 
(COPD) 
225, 163 1 year Beck 
Depression 
Inventory 
(continuous) 
Self-report 
abstinece, 
confirmed by 
salivary cotinine 
values (<20 
ng/ml)  
Multivariate 
OR=0.97, (95% 
CI 0.90-1.05, 
p=0.48) 
52.5% Data from one arm of 
randomized trial 
(SmokeStopTherapy), 
results for other arm not 
reported.  Salivary cotinine 
confirmation at 6 and 12 
months for all participants. 
Cooley et al.
33 
(United States) 
Non-Small 
Cell Lung 
Cancer 
(NSCLC) 
230, 165 6 months Center for 
Epidemiologi
cal Studies 
Depression 
Scale (>15 
=Depressed) 
Self-report 
(continuation) 
and biochemical 
variation with 
urinary cotinine 
Crude OR=3.9 
(95% CI 1.32-
11.49, p=0.014); 
Multivariate: 
OR= 2.85, (95% 
CI 0.85-9.54, 
p=.088) 
72.5% Observational study. 
Biochemical confirmation 
for all participants at 1
st
 
and 2
nd 
interviews. 
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Hopenhayn et al.
34
 
(United States) 
Lung cancer 
(stage I, II, 
IIIA cases) 
179, 89 1 year Hospital 
Anxiety and 
Depression 
Scale 
(Depression 
>10) 
Self-report 
(continuation & 
cessation) 
Multivariate: RR 
(Poisson)= 1.48, 
(95% CI 1.00-
2.17, p=<0.05) 
72.5% Observational study. 
Adjusted Poisson estimates 
used instead of raw 
numbers for multivariate 
estimate. Crude estimate 
obtained from reported 
raw numbers. 
  
Ng et al.
35
 
(Singapore) 
COPD 376, 275 1 year Hospital 
Anxiety and 
Depression 
Scale ( >7 as 
depressed) 
Self-report 
(continuation) 
 
 
Crude OR=2.08 
(95% CI 1.20-
3.60, p=0.009); 
Multivariate: 
OR= 2.85, (95% 
CI 01.17-4.52, 
p=.02) 
85% Observational study. 
Multivariate estimate 
adjusted for 10 other 
factors, including anxiety. 
Otten et al
36
 
(The Netherlands) 
Asthma 372, 372 22-24 Months Depressive 
Mood List 
(>21.8 = 
depressed) 
Self-Report 
(continuation) 
Adjusted 
OR=1.98 (95% 
CI 1.31-3.00, 
p<0.01) 
57.5% Population observational 
study of adolescents. 
Estimate used is from 
entire sample, however 
authors stated relationship 
between depressive 
feelings and smoking was 
similar for adolescents 
with or without asthma. 
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Analysis adjusted for age, 
sex, education. 
Papaioannou et al.
37
 
(Greece) 
 
 
COPD 241, 230 1 Year Beck 
Depression 
Inventory 
(≥19 = 
moderate or 
severe 
depressive 
symptoms) 
Self-report 
(continuation) 
  
Results not 
reported in paper. 
(23/26 depressed; 
44/49 non-
depressed 
smoking at 
follow-up) 
85% Observational study of 
patients without prior 
diagnosis of depression. 
Results obtained by email.  
 
No biochemical verification 
was used. 
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Wagena et al.
38
 
(The Netherlands) 
At risk for 
COPD or with 
COPD 
255,255 26 Weeks Beck 
Depression 
Inventory 
Score (≥15 = 
depressed) 
Self-report 
(cessation), 
confirmed by 
urinary cotinine 
≤60 ng/mL at wk 
4, 12 and 26 after 
target quit date 
(TQD) 
 
Association not 
reported in paper, 
but calculated 
from raw data 
reported in study 
(17/19 depressed 
versus 59/70 non-
depressed were 
smoking at 
follow-up) 
67.5% Data from randomized trial 
of buproprion hydrochloride 
and nortriptyline 
hydrochloride, but control 
group only (n=89) used to 
calculate estimates.  
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Table 2: Sensitivity analyses 
Sensitivity analysis SMD 95% CI I
2
 p-value 
<1 year follow-up (n=2) -.32 -.72 to .08 0% .327 
≥1 year follow-up (n=5) -.31 -.44 to -.18 7.7% .362 
CCAT≥60% (n=5) -.29 -.48 to -.10 16.8% .308 
CCAT<60% (n=2) -.35 -.53 to -.18 0% .756 
Adjusted estimates (n=5)+ -.34 -.46 to -.21 0% .471 
Unadjusted estimates (n=5)+ -.38 -.61 to -.14 23.2% .267 
Objectively measured cessation (n=3) -.32 -.55 to -.09 0% .619 
Self-report cessation (n=4) -.31 -.49 to -.14 30.8% .228 
+note – these analyses add to more than 7 studies as some studies provided both an 
unadjusted and adjusted estimate 
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Appendix A - Sample searches: 
 
MEDLINE on PubMed 
depressi*[MeSH Terms]) OR depressi*[Title/Abstract]  OR antidepress*[Title/Abstract] OR  mood 
disorders[Title/Abstract] OR Mood disorders[MeSH Terms] 
AND 
smok*[MeSH Terms] OR smok*[Title/Abstract] OR tobacco[MeSH Terms] OR tobacco[Title/Abstract]  
OR cigarette[Title/Abstract] OR cigar*[Title/Abstract] OR nicotine[Title/Abstract] OR nicotine[MeSH Terms] OR 
bupropion(Title/Abstract] OR bupropion[MeSH Terms] OR varenicline[Title/Abstract]  
AND 
lung diseases, obstructive[MeSH Terms] OR obstructive lung disease* [Title/Abstract] OR pulmonary 
disease[Title/Abstract]  OR Pulmonary Disease, Chronic Obstructive[MeSH Terms] OR Bronchitis, Chronic[MeSH 
Terms] OR bronchitis[Title/Abstract] OR asthma[MeSH Terms] OR bronchiectasis[MeSH Terms] OR 
bronchiectasis[Title/Abstract] OR Emphysema[MeSH Terms] OR    
Emphysema[Title/Abstract] OR pulmonary fibrosis[MeSH Terms] OR pulmonary fibrosis[Title/Abstract] OR 
respiratory symptom[Title/Abstract]  OR lung neoplasms[MeSH Terms] OR lung neoplasms[Title/Abstract]   
 
PsychINFO on OVID 
(depression OR depressive OR antidepression OR antidepressive OR mood disorders).mp 
AND 
(smoking OR smoker OR smokers OR tobacco OR cigarette OR cigar OR cigars OR nicotine OR nicotine OR 
bupropion OR varenicline).mp 
AND 
(obstructive lung diseases OR pulmonary disease OR Bronchitis OR asthma OR bronchiectasis OR Emphysema 
OR pulmonary fibrosis OR respiratory symptom OR lung neoplasms).mp 
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Appendix B 
Appendix B: Omitted studies that did not report the association between baseline depression and subsequent smoking  
Author  Sample 
Description 
Sample 
Size: 
Baseline, 
Follow-Up 
Longest  
Follow-Up 
Duration 
Depression Measures 
(Measured at Follow-Up 
Yes/No) 
Smoking 
Outcome 
Measures 
Results Comments 
        
Aguiar et al.
1 
Pulmonary 
disease in 274  
526,307 30 Months A diagnosis of depression, 
Taking sedative-hypnotics 
and/or antidepressants 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent – 
Author did not 
reply by  
 
        
Arnardottir et al.
2 
COPD 60,60 16 weeks (HADS), higher score 
indicates worse mental 
health   
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
 
Attebring et al.
3 
ACS, some of 
sample had 
pulmonary 
disease 
434,348 3 Months Sedatives/ Anti-
depressants at baseline 
Self-report Being on Sedatives/ 
Anti-depressants at 
baseline predicts odds 
for continued smoking 
at follow-up (OR=8.40, 
CI= 2.36-30.0) 
Email sent 
Berlin et al.
4
,  West et al.
5 
Asthma, COPD, 
Emphysema 
2009, ? 2.5 years 2 times or more visits to 
the doctor due to 
depression 
Self-report Depression is associated 
with higher nicotine 
dependence and urges. 
Email sent 
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Brito-Mutunayagam et al. 
6 
COPD 4060, 3206 3.5 Years Center for Epidemiologic 
Studies Depression Scale 
(CES-D), ≥16 = depressed 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
 Author will 
provide data after 
deadline 
Bucknall et al.
7 
COPD 464, 265 12 Months  HADS Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent   
Coultas et al.
8 
COPD 217, 151 6 Months CES-D Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent  
 
Garcia-Aymerich et al.
9,
 
10 
COPD 342, ? 8 years HADS Self-report  No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
        
Gudmundsson et al.  
11, 12 
COPD 416, 406 12 Months Hospital Anxiety and 
Depression Scale (HADS-
D), ≥8 = depressed 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Hanania et al. 
13 
, Vestbo et al.
14 
COPD 2118, ? 3 Years  Center for Epidemiologic 
Studies Depression Scale 
(CES-D), ≥16 = 
depressed. 
Self-reported depression 
or use of Anti-depressants 
Self-report Depression has no 
effect on smoking 
status. And, No 
association reported 
between depression and 
subsequent smoking 
Email sent 
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at baseline cessation  
Hasler et al.
15 
Asthma 591, 367 20 years Diagnostic interview Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Jones et al 
16 
COPD 158, 115 ? HADS Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Author was 
emailed on 19/2. 
They did not 
respond to 
previous request 
for PDF, so 
unlikely to reply 
to this data 
request. 
 
 
Joseph et al.
17 
Asthma 196, 90 12 months ? Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Kotz et al.
18 
COPD 228, 228 50 days (BDI) Beck Depression 
Inventory and (HADS) 
Hospital Anxiety and 
Depression Scale 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Katz et al.
19 
Asthma 374, 128 36 months CES-D, the higher scores 
the more depressed 
Self-report No association reported 
between depression and 
subsequent smoking 
Email sent 
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cessation 
Laitinen et al.
20 
 
COPD 739, ? 1-3 years, 
intended to 
follow-up 
for 10 years 
? Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Leander et al.
21 
Asthma 616, 460 13 years Gothenburg Quality-of-
Life Instrument (GQL) 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
LoConte et al.
22 
Non-small cell 
lung cancer 
(NSCLC) 
96,52 6 Months CES-D, ≥16 = depressed Self-report Depression levels were 
similar in current, ex-, 
and never smokers. No 
association reported 
between depression and 
subsequent smoking 
cessation. 
Email sent 
Loerbroks et al.
23 
Asthma 5114, 4010 8.5 years Depression scale 
developed by von Zerrsen 
Self-report High depression skores 
associated with never or 
current smoking status. 
No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Mancuso et al.
24 
Asthma 296, 197 1 year Geriatric Depression Scale 
≥11 = depressed 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Myrdal et al.
25 
Lung cancer 
(primary 
194, 132 22.5 months HADS Self-report No association reported 
between depression and 
Email sent 
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bronchogenic 
carcinoma of the 
lung) 
8-10 = probable 
depression, ≥11 = 
definite" clinical 
depression 
subsequent smoking 
cessation 
Neuman et al.
26 
Asthma 542, 515 8.6 years   HADS, ≥8 = depressed Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Oga et al.
27 
COPD 137, 72 5 years HADS Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Pahwa et al.
28 
 
Chronic 
bronchitis and 
Asthma 
14713, ? 7 years Distress scale developed 
by Kessler et al. 
Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Ringlever et al.
29 
Asthma 10087, 
6769 
24 months Depressive Mood List 
(DML), higher scores 
imply higher levels of 
depressive feelings 
Non-smokers Data base in this paper 
is rejected, however 
author was e-mailed for 
extra data  
Email sent 
        
Sarna et al.
30 
Non-small cell 
lung cancer 
(NSCLC) 
119, 119 6 months CES-D, ≥16 = depressed Self-report, 
confirmed by 
urinary 
cotinine at 
baseline and 3 
months 
No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
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follow-up 
  
Sherman et al.
41 
COPD 1914, 1150 12 months (CES-D), ≥10 = depressed Self-report Smokers were 47 % 
likely to be depressed. 
No association reported 
between depression and 
subsequent smoking 
cessation 
 
Simmons et al.
32 
Thoracic Cancer 177, 154 12 Months (CES-D) Center for 
Epidemiologic Studies 
Depression Scale + self-
reported history use of 
anti-depressants. 
Self-report , a 
proportion of 
the sample 
(n=44) were 
tested by 
collecting 
biochemical 
conformation 
of quit state by 
breath CO 
Smoking relapse was 
predicted by greater 
depression proneness 
(p=0.004) or previous 
depression treatment 
(p=0.042) 
Email sent 
Tashkin et al.
33 
COPD 200, 129 6 months History of depression University of 
Wisconsin 
Center for 
Tobacco 
Research and 
Intervention 
craving and 
withdrawal 
questionnaire 
? Email sent 
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Uyar et al.
34 
Unclear if 
sample had 
respiratory 
disease 
131, 131 24 weeks (BDI) Beck Depression 
Inventory Score 
 0-13 minimal depression, 
14-19 mild depression, 20-
28 moderate depression, 
and 29-63 severe 
depression 
Mesure CO 
levels to 
confirm status 
levels < 10 
ppm 
confirmed 
abstinent. 
Abstinence rates were 
higher in individuals 
with lower levels 
depression  
Email sent 
Van Sachayck et al.
35 
COPD 255, 214 1 year BDI Self-report, 
confirmed by 
by urinary 
cotinine 
values (cut-off 
point 60 
ng/ml) 
Depression had no 
effect on subsequent 
smoking cessation 
Email sent 
von Leupoldt et al.
36 
COPD  238, 238 3 weeks HADS, ≥8 = depressed Self-report No association reported 
between depression and 
subsequent smoking 
cessation 
Email sent 
Walker et al.
37 
Non-small cell 
lung cancer 
(NSCLC) 
43, ? Beck Depression 
Inventory Score (BDI) 
Self-report No association reported 
between depression and 
smoking. 
Email sent 
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Appendix C – Quality ratings 
Author Preamble Introduction Design Sampling 
Data 
Collection 
Ethical Matters Results/ 
Discussion 
Total Score 
(%) 
Christenhusz 
et al.
32
 4 5 4 4 2 0 4 4 67.5% 
Cooley et al.
33
 3 3 3 1 4 1 4 4 57.5% 
Hopenhayn et 
al.
34
 4 5 1 3 3 3 5 5 72.5% 
Ng et al.
35
 4 5 3 3 3 2 4 5 72.5% 
Otten et al.
36
 5 5 4 4 4 4 4 4 85% 
Papaioannou 
et al.
37
 4 4 3 1 1 4 2 2 52.5% 
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Wagena et 
al.
38
 5 5 5 4 3 3 4 5 85% 
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Appendix D – Funnel plot and test for bias 
 
 
 
Egger's test for small-study effects: Regress standard normal deviate of intervention 
effect estimate against its standard error 
 
 
Number of studies =  7                                 Root MSE      =   1.111   
  
Std_Eff Coef. Std. Err. t P>t [95% Conf. Interval] 
slope -.2889435 .1847927 -1.56 0.179 -.7639682 .1860811 
bias -.1176586 1.16425 -0.10 0.923 -3.110459 2.875142 
Test of H0: no small-study effects          P = 0.923    
